Torii Pharmaceuticals Start Phase II/III In Hyposensitization Therapy
This article was originally published in PharmAsia News
Executive Summary
Torii Pharmaceuticals announced July 31 it started Phase II clinical trials for TO-203, a hyposensitization drug for allergic asthma and rhinitis caused by house dust mites. The sublingual tablets extract protein from the allergen.